Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
NCT ID: NCT05269459
Last Updated: 2025-05-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
180 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-12-01
Study Completion Date
2029-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Post-traumatic stress disorder (PTSD) is a psychiatric disorder than may develop following a traumatic event including serious incidents, natural or human-caused disasters, violence, death of a loved one, receipt of traumatic news, or serious illness/hospitalization. While half of US adults experience trauma in their lifetime, most do not develop PTSD. However, those who do develop the disorder may have significant impairments and risk for functional dysfunction across multiple domains. While short term symptoms are the most common, some individuals develop chronic PTSD. These individuals may experience frightening and intrusive thoughts and memories of the event (flashbacks), have sleep disturbances, feel numb or detached, and be easily startled (hypervigilance).
This trial is a double-blind placebo controlled study of cannabidiol (CBD) for symptoms of PTSD in adults using liquid structure Formulation (Nantheia ATL5). Participants complete three weeks of baseline data collection including assessments of activity and sleep. Intervention is Nantheia ATL5 or placebo. Dose is initiated at 400mg BID and maintained over 8 weeks. Standardized symptom profile measurements, clinician assessments, laboratory testing, collection of inflammatory biomarkers, and suicide screening is completed throughout. Age- and gender-matched healthy population participants are enrolled and complete baseline data collection only. All participants may complete optional functional magnetic resonance imaging (fMRI).
This trial is a double-blind placebo controlled study of cannabidiol (CBD) for symptoms of PTSD in adults using liquid structure Formulation (Nantheia ATL5). Participants complete three weeks of baseline data collection including assessments of activity and sleep. Intervention is Nantheia ATL5 or placebo. Dose is initiated at 400mg BID and maintained over 8 weeks. Standardized symptom profile measurements, clinician assessments, laboratory testing, collection of inflammatory biomarkers, and suicide screening is completed throughout. Age- and gender-matched healthy population participants are enrolled and complete baseline data collection only. All participants may complete optional functional magnetic resonance imaging (fMRI).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder
NCT05132699
Posttraumatic Stress Disorder
Stress Disorders, Post-Traumatic
COMPLETED
PHASE1/PHASE2
Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI
NCT04550377
Post Traumatic Stress Disorder
Traumatic Brain Injury
RECRUITING
PHASE2
Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder
NCT04197102
Post Traumatic Stress Disorder
SUSPENDED
PHASE2
Nabilone in Cannabis Users With PTSD
NCT03251326
Cannabis
Post Traumatic Stress Disorder
TERMINATED
PHASE1/PHASE2
Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD
NCT02759185
Posttraumatic Stress Disorder
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Post-traumatic stress disorder (PTSD) is a psychiatric disorder than may develop following a traumatic event including serious incidents, natural or human-caused disasters, violence, death of a loved one, receipt of traumatic news, or serious illness/hospitalization. While half of US adults experience trauma in their lifetime, most do not develop PTSD. However, those who do develop the disorder may have significant impairments and risk for functional dysfunction across multiple domains. While short term symptoms are the most common, some individuals develop chronic PTSD. These individuals may experience frightening and intrusive thoughts and memories of the event (flashbacks), have sleep disturbances, feel numb or detached, and be easily startled (hypervigilance).
This trial is a single-site phase II, double-blind, placebo-controlled study of Nantheia ATL5 to study symptoms of Post-Traumatic Stress Disorder (PTSD) in adults. Participants will meet criteria for PTSD using the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Clinical Assessment of Pragmatics (CAPs-5) of ≥ 27. Suicidality is assessed using the Columbia Suicide Severity Rating Scale-Revised (CSSRS-R) at all study visits. Baseline psychopharmacotherapy and/or psychotherapy must be stable (unchanged) for 4 weeks prior to enrollment and should remain unchanged during study treatment. Effects of Nantheia ATL5 on self-reported quality of life (overall and health-related); functional status measurements of personal mobility and risk, and sleep dysfunction; neurobiological biomarkers of threat response (optional functional magnetic resonance imaging: fMRI), and serum inflammatory biomarkers (hs-CRP) implicated in PTSD pathophysiology will be assessed. Efficacy and tolerability will be assessed throughout intervention. Serum pregnancy (for participants of child bearing potential), urine drug screening, complete blood count (CBC), and Comprehensive Metabolic Panel are completed at every on-site visit. Optional consent will be sought from all PTSD and healthy population participants who agree to complete the functional magnetic resonance imaging (fMRI) procedures and providing an additional sample of blood to store for future unspecified research. Baseline characteristics of participants with PTSD will be evaluated overall and relative to participants without PTSD (healthy population) during a 3-week baseline period prior to randomization \[Nantheia ATL5 or placebo (PBO)\]. Healthy population participants will complete the study at end of baseline and participants with PTSD will be randomized 1:1 to Nantheia ATL5 or placebo (PBO). Study drug dose is initiated at 400mg BID and maintained for 8 weeks. Study drug is then withdrawn, and one week later safety measures including laboratory testing, assessment of AE's and CSSRS-R are repeated.
This trial is a single-site phase II, double-blind, placebo-controlled study of Nantheia ATL5 to study symptoms of Post-Traumatic Stress Disorder (PTSD) in adults. Participants will meet criteria for PTSD using the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Clinical Assessment of Pragmatics (CAPs-5) of ≥ 27. Suicidality is assessed using the Columbia Suicide Severity Rating Scale-Revised (CSSRS-R) at all study visits. Baseline psychopharmacotherapy and/or psychotherapy must be stable (unchanged) for 4 weeks prior to enrollment and should remain unchanged during study treatment. Effects of Nantheia ATL5 on self-reported quality of life (overall and health-related); functional status measurements of personal mobility and risk, and sleep dysfunction; neurobiological biomarkers of threat response (optional functional magnetic resonance imaging: fMRI), and serum inflammatory biomarkers (hs-CRP) implicated in PTSD pathophysiology will be assessed. Efficacy and tolerability will be assessed throughout intervention. Serum pregnancy (for participants of child bearing potential), urine drug screening, complete blood count (CBC), and Comprehensive Metabolic Panel are completed at every on-site visit. Optional consent will be sought from all PTSD and healthy population participants who agree to complete the functional magnetic resonance imaging (fMRI) procedures and providing an additional sample of blood to store for future unspecified research. Baseline characteristics of participants with PTSD will be evaluated overall and relative to participants without PTSD (healthy population) during a 3-week baseline period prior to randomization \[Nantheia ATL5 or placebo (PBO)\]. Healthy population participants will complete the study at end of baseline and participants with PTSD will be randomized 1:1 to Nantheia ATL5 or placebo (PBO). Study drug dose is initiated at 400mg BID and maintained for 8 weeks. Study drug is then withdrawn, and one week later safety measures including laboratory testing, assessment of AE's and CSSRS-R are repeated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
PTSD
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Double-Blind Placebo Controlled Study
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Investigators
Outcome Assessors
Participants and study personnel are blinded to treatment assignment. Randomization will occur in blocks based on self-reported marijuana use (yes/no). Randomization schedule will be provided by the statistician to the research pharmacist for study drug dispensing.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cannabidiol Administered as Nantheia ATL5 Group
Cannabidiol (CBD) as Liquid Structure Formulation Nantheia ATL5 400mg will be administered twice a day in 100mg softgel capsules to CBD Group. Each 100mg softgel contains 10% CBD.
Group Type
EXPERIMENTAL
Cannabidiol Administered as Nantheia ATL5
Intervention Type
DRUG
Participants will take 4 gel capsules twice daily containing 100mg of Nantheia ATL5.
Placebo Group
Matching placebo capsules will be administered twice a day to Placebo Group.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Participants will take 4 matching gel capsules twice daily containing no active drug.
Control Group
Baseline data collection only will be collected from Control group.
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cannabidiol Administered as Nantheia ATL5
Participants will take 4 gel capsules twice daily containing 100mg of Nantheia ATL5.
Intervention Type
DRUG
Placebo
Participants will take 4 matching gel capsules twice daily containing no active drug.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
CBD
PBO
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability and willingness to provide informed consent
* Stated willingness to comply with all study procedures and availability for duration of the study
* Aged 21-65 years
* Able to read and communicate in English
* Tetrahydrocannabinol (THC) use less than 3 days per week
PTSD Participants
* Meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for a current diagnosis of Post-Traumatic Stress Disorder (PTSD) on the Mini-Mental State examination (MMS), with symptoms present for at least 1 month
* Clinician administered Clinical Assessment of Pragmatics (CAPs) score ≥27 at study enrollment and start of Cannabidiol (CBD) observation
* Stable psychopharmacologic and/or psychotherapeutic intervention for 4 weeks prior to enrollment
* Stated willingness to comply with all study procedures and availability for duration of the study
* Aged 21-65 years
* Able to read and communicate in English
* Tetrahydrocannabinol (THC) use less than 3 days per week
PTSD Participants
* Meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for a current diagnosis of Post-Traumatic Stress Disorder (PTSD) on the Mini-Mental State examination (MMS), with symptoms present for at least 1 month
* Clinician administered Clinical Assessment of Pragmatics (CAPs) score ≥27 at study enrollment and start of Cannabidiol (CBD) observation
* Stable psychopharmacologic and/or psychotherapeutic intervention for 4 weeks prior to enrollment
Exclusion Criteria
* Current use of prescribed or commercially available CBD products, including Epidiolex®
* Suicidal ideation (as defined by answer of "yes" to item 4 or 5 on the baseline Columbia Suicide Severity Rating Scale (C-SSRS) or attempt within 6 months prior to enrollment)
* Cognitive impairment in the clinical judgment of the investigator that would impact ability to complete study assessments or confound study results (e.g., neurodegenerative condition or other)
* Meets criteria for substance or alcohol use disorder of moderate or greater severity within 6 months prior to study enrollment based on the Mini-Mental State examination (MMS); nicotine dependence permitted
* Self-reported cannabis use on \> 3 days/week starting 4 weeks prior to enrollment
* Positive urine drug screen for illicit substances other than cannabis
* Pregnant \[confirmed by serum human chorionic gonadotropin (hCG) test\], or breastfeeding
* Co-morbid medical conditions or concomitant treatments that may adversely impact ability to participate in the trial in the clinical judgment of the investigator \[e.g., significant immunosuppression due to active chemotherapy, recent organ transplant, uncontrolled diabetes, glomerular filtration rate (GFR) \< 25ml/min or on dialysis, recent acute myocardial infarction (MI), Class IV heart failure, or taking any high-risk drugs for drug-drug interactions\]
* Treatment with another investigational drug or other intervention within 3 months prior to enrollment
* History of psychosis (schizophrenia, schizophreniform disorder, schizoaffective disorder, or substance induced psychosis), active bipolar disorder, or borderline personality disorder diagnosed by a mental health professional
* History of open head injury
* Self-report of exposure to trauma within 30 days prior to enrollment
* Active military service in the 30 days prior to enrollment
* Inpatient psychiatric hospitalization within 6 months prior to enrollment
* Seizure in the last 6 months
* Use of concomitant anti-viral human immunodeficiency virus (HIV) medications (PrEP permitted)
Control Participants
* History of diagnosed PTSD
* Pregnant (self-reported) or breastfeeding
Participants who consent to functional magnetic resonance imaging (fMRI) procedures
* Claustrophobia, pregnancy, or any condition (e.g., significant hearing difficulties) that would preclude MRI scanning, in the clinical judgment of the investigator
* Presence of metal objects in or on the body (e.g., pacemakers, aneurysm clips, metallic prostheses, bone plates, braces, orthodontic devices, cochlear implants/hearing aids, non-removable piercings/implants or metallic-ink tattoos, or shrapnel fragments)
* Other confounding medical conditions (e.g., Tourette's or Tic Disorder) that would preclude MRI scanning, in the clinical judgement of the investigator
PTSD Participants
* Index trauma before age 18 and no other traumatic experiences which could relate/identify as part of PTSD
* History of allergic reaction or significant adverse events (AE) related to cannabis, CBD, or THC
* Currently involved in events giving rise to PTSD
* Alanine transaminase (ALT)/Aspartate transaminase (AST)/Bilirubin \> 2 x upper limit of normal (ULN) at screening (abnormalities on the comprehensive metabolic panel or complete blood count deemed to be of clinical significance in the judgement of the investigator and clinical team will be evaluated in the clinical context of the participant's history and physical examination to determine eligibility and testing may be repeated if clinically appropriate at the discretion of the investigator)
* Refusal to use at least one form of birth control throughout study participation \[including, but are not limited to, male or female condoms, diaphragm, or cervical cap (all with or without spermicide) abstinence, or hormonal/implanted birth control, e.g., pill, injection, intra-uterine device (IUD), implant\] by participants who can become pregnant
* Suicidal ideation (as defined by answer of "yes" to item 4 or 5 on the baseline Columbia Suicide Severity Rating Scale (C-SSRS) or attempt within 6 months prior to enrollment)
* Cognitive impairment in the clinical judgment of the investigator that would impact ability to complete study assessments or confound study results (e.g., neurodegenerative condition or other)
* Meets criteria for substance or alcohol use disorder of moderate or greater severity within 6 months prior to study enrollment based on the Mini-Mental State examination (MMS); nicotine dependence permitted
* Self-reported cannabis use on \> 3 days/week starting 4 weeks prior to enrollment
* Positive urine drug screen for illicit substances other than cannabis
* Pregnant \[confirmed by serum human chorionic gonadotropin (hCG) test\], or breastfeeding
* Co-morbid medical conditions or concomitant treatments that may adversely impact ability to participate in the trial in the clinical judgment of the investigator \[e.g., significant immunosuppression due to active chemotherapy, recent organ transplant, uncontrolled diabetes, glomerular filtration rate (GFR) \< 25ml/min or on dialysis, recent acute myocardial infarction (MI), Class IV heart failure, or taking any high-risk drugs for drug-drug interactions\]
* Treatment with another investigational drug or other intervention within 3 months prior to enrollment
* History of psychosis (schizophrenia, schizophreniform disorder, schizoaffective disorder, or substance induced psychosis), active bipolar disorder, or borderline personality disorder diagnosed by a mental health professional
* History of open head injury
* Self-report of exposure to trauma within 30 days prior to enrollment
* Active military service in the 30 days prior to enrollment
* Inpatient psychiatric hospitalization within 6 months prior to enrollment
* Seizure in the last 6 months
* Use of concomitant anti-viral human immunodeficiency virus (HIV) medications (PrEP permitted)
Control Participants
* History of diagnosed PTSD
* Pregnant (self-reported) or breastfeeding
Participants who consent to functional magnetic resonance imaging (fMRI) procedures
* Claustrophobia, pregnancy, or any condition (e.g., significant hearing difficulties) that would preclude MRI scanning, in the clinical judgment of the investigator
* Presence of metal objects in or on the body (e.g., pacemakers, aneurysm clips, metallic prostheses, bone plates, braces, orthodontic devices, cochlear implants/hearing aids, non-removable piercings/implants or metallic-ink tattoos, or shrapnel fragments)
* Other confounding medical conditions (e.g., Tourette's or Tic Disorder) that would preclude MRI scanning, in the clinical judgement of the investigator
PTSD Participants
* Index trauma before age 18 and no other traumatic experiences which could relate/identify as part of PTSD
* History of allergic reaction or significant adverse events (AE) related to cannabis, CBD, or THC
* Currently involved in events giving rise to PTSD
* Alanine transaminase (ALT)/Aspartate transaminase (AST)/Bilirubin \> 2 x upper limit of normal (ULN) at screening (abnormalities on the comprehensive metabolic panel or complete blood count deemed to be of clinical significance in the judgement of the investigator and clinical team will be evaluated in the clinical context of the participant's history and physical examination to determine eligibility and testing may be repeated if clinically appropriate at the discretion of the investigator)
* Refusal to use at least one form of birth control throughout study participation \[including, but are not limited to, male or female condoms, diaphragm, or cervical cap (all with or without spermicide) abstinence, or hormonal/implanted birth control, e.g., pill, injection, intra-uterine device (IUD), implant\] by participants who can become pregnant
Minimum Eligible Age
21 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ananda Scientific Inc
UNKNOWN
Sponsor Role
collaborator
University of Texas at Austin
OTHER
Sponsor Role
collaborator
University of Nebraska
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthew Rizzo, MD
Role: PRINCIPAL_INVESTIGATOR
University of Nebraska
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Nebraska Medical Center
Omaha, Nebraska, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Association, A. P. (2013). Diagnostic and Statistical Manual 5. Washington D.C.: American Psychiatric Association.
Reference Type
BACKGROUND
Association, A. P. (2017). Medications for PTSD. Retrieved from https://www.apa.org/ptsd-guideline/treatments/medications
Reference Type
BACKGROUND
Stanciu CN, Brunette MF, Teja N, Budney AJ. Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review. Psychiatr Serv. 2021 Apr 1;72(4):429-436. doi: 10.1176/appi.ps.202000189. Epub 2021 Feb 3.
Reference Type
BACKGROUND
Wall MB, Pope R, Freeman TP, Kowalczyk OS, Demetriou L, Mokrysz C, Hindocha C, Lawn W, Bloomfield MA, Freeman AM, Feilding A, Nutt D, Curran HV. Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity. J Psychopharmacol. 2019 Jul;33(7):822-830. doi: 10.1177/0269881119841568. Epub 2019 Apr 23.
Reference Type
BACKGROUND
Sholler DJ, Schoene L, Spindle TR. Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies. Curr Addict Rep. 2020 Sep;7(3):405-412. doi: 10.1007/s40429-020-00326-8. Epub 2020 Jul 25.
Reference Type
BACKGROUND
Marx BP, Lee DJ, Norman SB, Bovin MJ, Sloan DM, Weathers FW, Keane TM, Schnurr PP. Reliable and clinically significant change in the clinician-administered PTSD Scale for DSM-5 and PTSD Checklist for DSM-5 among male veterans. Psychol Assess. 2022 Feb;34(2):197-203. doi: 10.1037/pas0001098. Epub 2021 Dec 23.
Reference Type
BACKGROUND
Hurd YL. Leading the Next CBD Wave-Safety and Efficacy. JAMA Psychiatry. 2020 Apr 1;77(4):341-342. doi: 10.1001/jamapsychiatry.2019.4157. No abstract available.
Reference Type
BACKGROUND
Elsaid S, Kloiber S, Le Foll B. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. Prog Mol Biol Transl Sci. 2019;167:25-75. doi: 10.1016/bs.pmbts.2019.06.005. Epub 2019 Aug 28.
Reference Type
BACKGROUND
Andrewes DG, Jenkins LM. The Role of the Amygdala and the Ventromedial Prefrontal Cortex in Emotional Regulation: Implications for Post-traumatic Stress Disorder. Neuropsychol Rev. 2019 Jun;29(2):220-243. doi: 10.1007/s11065-019-09398-4. Epub 2019 Mar 14.
Reference Type
BACKGROUND
Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017 Apr;19(4):23. doi: 10.1007/s11920-017-0775-9.
Reference Type
BACKGROUND
Elms L, Shannon S, Hughes S, Lewis N. Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series. J Altern Complement Med. 2019 Apr;25(4):392-397. doi: 10.1089/acm.2018.0437. Epub 2018 Dec 13.
Reference Type
BACKGROUND
Hori H, Kim Y. Inflammation and post-traumatic stress disorder. Psychiatry Clin Neurosci. 2019 Apr;73(4):143-153. doi: 10.1111/pcn.12820. Epub 2019 Feb 21.
Reference Type
BACKGROUND
Jackson BN, Weathers FW, Jeffirs SM, Preston TJ, Brydon CM. The revised Clinician-Administered PTSD scale for DSM-5 (CAPS-5-R): Initial psychometric evaluation in a trauma-exposed community sample. J Trauma Stress. 2025 Feb;38(1):40-52. doi: 10.1002/jts.23093. Epub 2024 Aug 23.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0159-22-FB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluating Safety and Efficacy of Cannabis in Participants With Chronic Posttraumatic Stress Disorder
NCT02517424
COMPLETED
PHASE2
Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD)
NCT00965809
UNKNOWN
PHASE4
Inhaled Cannabis for Treatment of PTSD
NCT07224698
NOT_YET_RECRUITING
PHASE2
Mitigating PTSD-CUD After Sexual Assault
NCT05989841
RECRUITING
PHASE1/PHASE2
Cannabidiol and Prolonged Exposure
NCT03518801
COMPLETED
PHASE2
Short-Term Exposure for PTSD
NCT02874898
COMPLETED
NA
Effects of Drugs on Stress Memories
NCT06471647
COMPLETED
EARLY_PHASE1
Functional Outcomes of Cannabis Use (FOCUS) in Veterans With Posttraumatic Stress Disorder
NCT04565028
RECRUITING
NA
Study of Cannabidiol and Neuroimaging on Stress
NCT07278505
RECRUITING
PHASE1/PHASE2
Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)
NCT01188694
COMPLETED
PHASE2
Treating Insomnia & Nightmares After Trauma: Impact on Symptoms & Quality of Life
NCT01009112
COMPLETED
NA
TIMBER Psychotherapy and Ketamine Single Infusion in Chronic PTSD
NCT02766192
UNKNOWN
NA
Effect of Extended Cannabis Abstinence on PTSD Symptoms
NCT05162651
RECRUITING
NA
Amantadine for Treatment of Symptoms of the Post-traumatic Confusional State
NCT00693121
COMPLETED
PHASE4
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
NCT05243329
UNKNOWN
PHASE2
Loving-Kindness Meditation for PTSD
NCT01962714
COMPLETED
NA
An Investigation of the Biological and Neuronal Mechanisms of Post Traumatic Stress Disorder, Depression and Post-Concussive Syndrome Onset Following a Traumatic Brain Injury
NCT02019654
COMPLETED
Ganaxolone in Posttraumatic Stress Disorder (PTSD)
NCT01339689
COMPLETED
PHASE2
Exploring Nitrous Oxide Effects for Post Traumatic Stress Disorder (PTSD)
NCT03375294
COMPLETED
PHASE2
Mindfulness and Present Centered Therapies for PTSD: Efficacy and Mechanisms
NCT01347749
COMPLETED
NA
Prevention of Posttraumatic Stress Disorder (PTSD) With Diazepam
NCT01221883
UNKNOWN
PHASE4
Effect of Propranolol on Preventing Posttraumatic Stress Disorder
NCT00158262
COMPLETED
PHASE4
Enhancing Week-long Psychological Treatment for PTSD With Ketamine
NCT05737693
RECRUITING
PHASE2
The Effects of Home-Based Telemental Health for Rural Veterans With PTSD
NCT02295410
COMPLETED
The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD
NCT06414356
RECRUITING
PHASE4